Elekta: Year-end report May - April 2008/09

STOCKHOLM, Sweden--(Business Wire)--
Regulatory News:

• Order bookings rose 18* percent. Order backlog at an all time high level of
SEK 7,267 M. • Net sales amounted to SEK 6,689 M, an increase by 18* percent. •
Operating profit rose 28 percent to SEK 830 M (650). • Net profit amounted to
SEK 546 M (406). • Earnings per share increased by 35 percent to SEK 6.00
(4.44). • Cash flow from operating activities improved to SEK 740 M (319). Cash
flow after investments was positive SEK 580 M (neg. 280). • The Board proposes
an increase of the dividend to SEK 2.00 (1.75) per share, corresponding to
around SEK 184 M and 33 percent of net profit. • In fiscal year 2009/10, net
sales are expected to grow by more than 8 percent in local currency. Operating
profit in SEK is expected to grow by more than 35 percent.

* Compared to last fiscal year at unchanged exchange rates.

President and CEO Tomas Puusepp comments

I am pleased with our performance during the fiscal year 2008/09 considering a
challenging environment and global recession. Earnings per share grew by 35
percent and net sales and operating profit increased in line with our guidance.
As expected delivery volumes were high during the fourth quarter. Cash flow from
operating activities improved significantly reaching SEK 740 M for the year
where the main drivers were higher operating profit and broadly unchanged
working capital. Days Sales Outstanding, DSO were reduced to 76 days. As a
consequence of these improvements, we reduced the net debt to equity ratio to
0.31. Our balance sheet remains strong.

Order bookings in the fourth quarter were strong and for the year order bookings
increased in all regions and product areas. The order backlog continued to reach
"all time high" reflecting strong business growth.

Elekta continues to strengthen its market position proven by increased market
shares on new sales. Demand for our clinical solutions, products and services
remains strong and Elekta`s systems are now used in over 5,000 hospitals
worldwide. This broad and large customer base is a good platform for future
growth. Aftermarket and software sales are increasing in importance reflecting
customers` demand for comprehensive and efficient solutions and Elekta`s
commitment to life cycle services.

Elekta has today the most attractive and comprehensive product portfolio in the
market. Going forward, Elekta will increase investments in research and
development as a relation to net sales and will further develop collaborations
with key universities and other partners to bring new innovations for human care
to the market. We will thereby ensure our continued leadership in image guided
radiation therapy, stereotactic radiotherapy/radiosurgery and workflow
solutions. We will also further expand geographically including emerging markets
and therefore we continue to invest in clinically meaningful and affordable
technology such as Elekta Compact.

Steps are taken to improve efficiency by streamlining the organization and
realizing synergies following acquisitions made. This will result in a reduction
of the workforce and will lead to a cost reduction of SEK 100 M on an annual
basis. The cost of implementing these measures is estimated to SEK 40 M. In
2009/10, operating costs are estimated to grow by around 5 percent in local
currency.

Currency markets continue to be unstable. In line with our hedging policy, we
are currently hedged at approximately 70 percent for the fiscal year 2009/10.
Currency movements are expected to have a positive effect on results in the
fiscal year 2009/10 by SEK 250 M, based on present exchange rates.

The economic slowdown has so far had a limited effect on investments in cancer
care. However, the uncertainty is higher than before due to the global scale of
the financial crisis. There might be less availability of finance for private
customers and future health care spending could be negatively effected.

For the full fiscal year 2009/10 net sales is expected to grow by more than 8
percent in local currency and operating profit in SEK is estimated to increase
by more than 35 percent. In the long term, the objectives are to reach an
average organic sales growth of more than 10 percent in local currency.
Operating profit growth in SEK should exceed sales growth.

Tomas Puusepp President and CEO

About Elekta

Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated state of the art tools and treatment planning systems for
radiation therapy and radiosurgery, as well as workflow enhancing software
systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare providers
and patients, Elekta aims to improve, prolong and even save patient lives,
making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000
hospitals globally, and every day more than 100,000 patients receive diagnosis,
treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is
located in Stockholm, Sweden, and the company is listed on the Nordic Exchange
under the ticker EKTAb. For more information about Elekta, please visit
www.elekta.com.

This information was brought to you by Cision http://www.cisionwire.com

For further information, please contact:
Tomas Puusepp, President and CEO, Elekta AB (publ)
Tel: +46 8 587 25 520, e-mail: tomas.puusepp@elekta.com
or
Håkan Bergström, CFO, Elekta AB (publ)
Tel: +46 8 587 25 547, e-mail: hakan.bergstrom@elekta.com
or
Lena Schattauer, Investor Relations, Elekta AB (publ)
Tel: +46 8 587 25 499, e-mail: lena.schattauer@elekta.com
or
Stina Thorman, Investor Relations, Elekta AB (publ)
Tel: +46 8 587 25 437, e-mail: stina.thorman@elekta.com

Copyright Business Wire 2009